Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,500
Closed -$291K 34
2024
Q3
$291K Hold
1,500
0.08% 141
2024
Q2
$348K Hold
1,500
0.06% 175
2024
Q1
$323K Sell
1,500
-3,500
-70% -$820K 0.01% 249
2023
Q4
$1.29M Sell
5,000
-2,000
-29% -$491K 0.05% 162
2023
Q3
$1.8M Sell
7,000
-200
-3% -$53.5K 0.14% 110
2023
Q2
$2.05M Buy
7,200
+500
+7% +$149K 0.1% 86
2023
Q1
$1.86M Sell
6,700
-700
-9% -$194K 0.05% 119
2022
Q4
$2.05M Sell
7,400
-6,800
-48% -$1.92M 0.2% 95
2022
Q3
$467K Buy
+14,200
New +$3.02M 0.25% 75
2021
Q3
Sell
-6,400
Closed -$272K 406
2021
Q2
$272K Buy
+6,400
New +$1.94M 0.12% 150
2021
Q1
Sell
-13,600
Closed -$77K 474
2020
Q4
$77K Buy
+13,600
New +$3.51M 0.01% 263
2020
Q1
Sell
-10,500
Closed -$290K 213
2019
Q4
$290K Buy
+10,500
New +$2.91M 0.04% 104
2019
Q2
Sell
-11,100
Closed -$1K 272
2019
Q1
$1K Sell
11,100
-1,400
-11% -$441K ﹤0.01% 261
2018
Q4
$56K Buy
12,500
+6,200
+98% +$1.98M 0.02% 203
2018
Q3
$228K Buy
+6,300
New +$2.17M 0.06% 159

Other funds holding BIIB

XR Securities's BIIB Position: Q2 2023 in Review

XR Securities sold out of Biogen (BIIB) in Q2 2023, closing a stake of 1,122 shares — an estimated $334K sold.

XR Securities first reported a position in BIIB in Q3 2018 and held it in 11 quarters. The position peaked at $1.87M in Q3 2019. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

  • XR Securities reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
  • XR Securities sold 1,122 Biogen shares in Q2 2023, an estimated $334K.
  • XR Securities first reported a position in Biogen in Q3 2018 and held it in 11 quarters.
  • XR Securities's Biogen position peaked at $1.87M in Q3 2019.
  • 1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on XR Securities's 13F filing for Q2 2023, filed 8 Aug 2023.